Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.

about

Brentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome - a case report and discussion

P2860

Q35924909-476D9235-F636-406F-88DB-DD1C2F2D14EC

P2860

Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.

Item

http://www.wikidata.org/entity/Q38227567

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.

@en

type

Item

label

Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.

@en

prefLabel

Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.

@en

P1476

Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant

@en

P2093

Lalit Kumar

http://www.w3.org/2001/XMLSchema#string

Naveed Iqbal

http://www.w3.org/2001/XMLSchema#string

P2860

Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study.

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease.

Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy.

P304

605691

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/605691

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P50

Nida Iqbal

P577

2014-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263779110

http://www.w3.org/2001/XMLSchema#string

P698

25006506

http://www.w3.org/2001/XMLSchema#string

P921

autotransplantation

P932

4003874

http://www.w3.org/2001/XMLSchema#string

Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.

about

P2860

P2860

Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P5875

P698

P921

P932